Lilly cuts Zepbound vial prices as obesity drug competition heats up
US pharma major Eli Lilly (NYSE: LLY) has lowered the price of Zepbound (tirzepatide) single-dose vials on its Lilly Direct platform, widening access in a fast-moving obesity market. The 2.5-mg starting dose now matches the $299 monthly price set for the multi-dose pen awaiting US approval.
The 5-mg vial will cost $399 per month and higher doses $449 via the company’s Self Pay Journey Program. Regular prices outside the program range from $599 to $1,049. The update follows Lilly’s recent most-favored nation pricing deal with the Trump administration for Zepbound, Mounjaro (tirzepatide) and orforglipron.
“Far too many people who need obesity treatments still face cost and coverage barriers,” said Ilya Yuffa, president, Lilly USA and Global Customer Capabilities. He added that the company will continue expanding delivery options to support access for more patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze